Authors: Mary A. Williamson Mt(ascp) Phd,L. Michael Snyder Md
Do not use sodium azide in collection tubes.
Hemolysis produces false-negative results.
Hemoglobin concentrations >100 mg/dL may interfere.
Confirmation
Sample pretreatment required
Gas chromatography: derivatization may be necessary
HPLC: preferred technique for distinguishing metabolites
Limit of quantitation: 50 μg/mL
SCREENING FOR FETAL CHROMOSOME ABNORMALITIES AND NEURAL TUBE DEFECTS
Definition
Noninvasive testing with goal of limiting invasive diagnostic procedures that carry risk to pregnancy
Use
Screening modalities have been developed for Down syndrome/trisomy 21 detection because trisomy 21 is the most common viable autosomal chromosome abnormality. However, screening also provides specific risk assessment for trisomy 18 and neural tube defects.
In addition, with inclusion of early ultrasound examination, increased fetal nuchal translucency may indicate other chromosome abnormalities including Turner syndrome (45,X), trisomy 13, and triploidy.